NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-OD-17-052 from the NIH Guide for Grants and Contracts
Notice NOT-AA-17-002 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-245 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research.
Funding Opportunity PA-17-246 from the NIH Guide for Grants and Contracts. This FOA issued by AHRQ invites grant applications for funding to conduct exploratory and developmental research grants (R21) for projects in the early and conceptual stages of development that will contribute to the evidence base of how health information technology (IT) improves health care quality and outcomes.
Funding Opportunity PA-17-248 from the NIH Guide for Grants and Contracts. The overarching goal of this Funding Opportunity Announcement (FOA) is to support collaborative pilot projects to generate new ideas and approaches to reduce the incidence and/or severity of auto-inflammatory or autoimmune adverse events in the setting of cancer immunotherapy. In order to facilitate formation of multidisciplinary teams with expertise in mechanisms of cancer immunology/immunotherapy as well as immune tolerance and/or autoimmunity, teams that include (a) a current NCI grantee and a current NIAID grantee, or (b) a current NCI grantee and a current NIAMS grantee, are encouraged to propose collaborative pilot projects that utilize their complementary and synergistic expertise.
Notice NOT-HL-17-499 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-498 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-500 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-502 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-505 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-504 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-503 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-497 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-496 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-506 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-18-004 from the NIH Guide for Grants and Contracts. Avenir means future in French, and the Avenir Award Program for Research on Substance Abuse and HIV/AIDS looks toward the future by supporting early stage investigators (ESI) proposing highly innovative studies that address NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support creative individuals who wish to pursue innovative research at the nexus of substance abuse and HIV/AIDS. The nexus with drug abuse should be clearly described. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support research approaches, both basic and clinical, which have the potential to benefit substance using populations with or at risk for HIV/AIDS by reducing HIV incidence, improving therapies for HIV, reducing the impact of comorbid conditions, and ultimately, eradicating HIV.
Notice NOT-HL-17-501 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-17-241 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) is committed to reducing cancer related health disparities that affect all health disparity and underserved populations in the United States and to supporting research education, training and capacity building within, and near these communities. The NCI established the Center to Reduce Cancer Health Disparities (CRCHD) to strengthen cancer research by: addressing cancer health disparities; advising on strategic priorities, program direction, and scientific policy to strengthen cancer disparities research and training; and leading NCIs efforts to enhance scientific workforce diversity through the training of students and investigators from underrepresented backgrounds.
Funding Opportunity PA-17-239 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications that propose to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer epidemiology by supporting the analysis of existing genetic or genomic datasets, possibly in combination with environmental, outcomes, behavioral, lifestyle, and molecular profiles data. Applications to this FOA are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.
Funding Opportunity PA-17-243 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications that propose to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer epidemiology by supporting the analysis of existing genetic or genomic datasets, possibly in combination with environmental, outcomes, behavioral, lifestyle, and molecular profiles data. Applications to this FOA are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.